Skip to main content
Premium Trial:

Request an Annual Quote

Sense Biodetection Strikes UK Distribution Deal for COVID-19 Point-of-Care Test

NEW YORK — British molecular diagnostics firm Sense Biodetection said on Wednesday that it has signed a deal for the distribution of its Veros COVID-19 test in the UK with Una Health.

The test runs on the company's single-use, instrument-free Veros point-of-care platform, which uses a proprietary enyzmatic process to provide results in around 15 minutes without the need for any reader or power supply.

Sense said that the deal with Stoke-on-Trent, England-based Una is the latest step toward the rollout of the Veros system as it awaits regulatory approval for the COVID-19 test in the US and the UK.

"Una's strong relationships with customers in the point-of-care segment will be well served by the benefits that our rapid Veros Covid test can bring to the healthcare delivery process, providing the confidence of lab quality results wherever they are needed," Sense Chief Commercial Officer Ryan Roberts said in a statement.

In November, Sense raised an additional $15 million in an expanded Series B funding round, bringing the total amount raised in the round to $65 million.